Automating DNA assembly to drive forward the engineering of biology and unlock new applications

Product design and development firm Cambridge Consultants and SGI-DNA, a Synthetic Genomics Inc. company in San Diego, CA, USA, today announce that they will be installing the first BioXp™ 3200 System in the UK. The implementation will drive forward the use of automation in the emerging fields of biodesign and synthetic biology.

The BioXp™ 3200 System is the world’s first benchtop automated genomic workstation that rapidly synthesizes high-quality, double-stranded DNA fragments and clones into any vector in an overnight run.  

Cambridge Consultants is an early leader in the fast-emerging synthetic biology sector. With its in-house facilities, delivering rapid turnaround and innovative products, the BioXp™ 3200 System is a natural fit for the laboratory workflow and has numerous applications, including protein production, antibody library generation, and cell engineering.

As well as medical breakthroughs, this could also unlock a whole host of novel applications in areas such as consumer products, novel foods and biofuels.  

Biodesign has wide-ranging impact and is dependent on the speed and efficiency of generating and analyzing genes. Cambridge Consultants is working with a variety of companies to help improve the systems and equipment used in biodesign; the BioXp™ 3200 System will help researchers in pursuit of solving these challenges.

Richard Hammond, head of synthetic biology at Cambridge Consultants said­­, “We believe that the future of biodesign lies in automating processes and in turn increasing experimental throughput and reducing the time needed to develop new products. SGI-DNA shares this philosophy, and the BioXp™ 3200 instrument is a great example of this approach benefitting the synthetic biology community.”

SGI-DNA President Nathan Wood said, “The future of scientific advancement is automation. By installing the BioXp™ 3200 System at Cambridge Consultants’ innovative and world-class laboratories, more groups in Europe can benefit from custom DNA projects.”

More information is available at sgidna.com/bxp3200

 

Notes to editors

About Cambridge Consultants
Cambridge Consultants develops breakthrough products, services and intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 60 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 800 team members, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA), Tokyo (Japan) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, energy and wireless communications.

Visit us: www.cambridgeconsultants.com

About Capgemini Invent
As the digital innovation, design and transformation brand of the Capgemini Group, Capgemini Invent enables CxOs to envision and shape the future of their businesses. Located in nearly 40 studios and more than 60 offices around the world, it comprises a 10,000+ strong team of strategists, data scientists, product and experience designers, brand experts and technologists who develop new digital services, products, experiences and business models for sustainable growth.

Capgemini Invent is an integral part of Capgemini, a global leader in partnering with companies to transform and manage their business by harnessing the power of technology. The Group is guided everyday by its purpose of unleashing human energy through technology for an inclusive and sustainable future. It is a responsible and diverse organization of over 325,000 team members in more than 50 countries. With its strong 55-year heritage and deep industry expertise, Capgemini is trusted by its clients to address the entire breadth of their business needs, from strategy and design to operations, fueled by the fast evolving and innovative world of cloud, data, AI, connectivity, software, digital engineering and platforms. The Group reported in 2021 global revenues of €18 billion.

Get The Future You Want

Visit us at www.capgemini.com/invent

 

About SGI-DNA

SGI-DNA, a wholly owned subsidiary of Synthetic Genomics Inc., provides genomic solutions to advance scientific discovery. SGI-DNA’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. SGI-DNA’s genomic services include whole genome sequencing, DNA synthesis, library design, bioinformatics, cell engineering, and plasmid DNA cloning and purification. SGI-DNA’s reagents include a complete suite of Gibson Assembly® and Site Directed Mutagenesis kits as well as optimized cell lines. To further enable the synthetic biology workflow, SGI-DNA offers the BioXp™ 3200 System. This fully automated genomics workstation allows the creation of double stranded DNA fragments, automated cloning, as well as Next Generation Sequencing DNA library preparation. Building on scientific breakthroughs from J. Craig Venter, Hamilton Smith, Clyde Hutchison, Daniel Gibson and their teams, SGI-DNA is committed to reducing barriers associated with synthetic biology. More information is available at www.sgidna.com.

 

SGI-DNA Contact

Liz Liner, Synthetic Genomics

+1 858-433-2213

pr@sgidna.com

  • synthetic biology

PRESS CONTACTS

WE Communications

Matt
Urquhart